Skip to main content
SLAS2024 Main banner
Sartorius Ad
Back

Vasudev Kantae, PhD (he/him/his)

AstraZeneca, England, United Kingdom

Vasudev Kantae has more than 10 years’ experience in the field of bioanalysis employing mass spectrometry. In 2019, he joined AstraZeneca-UK to lead the mass spectrometry strategy implementing the quantitative (bio)analysis thrust. This has enabled the development of novel cellular and biochemical workflows to support SAR profiling and bespoke mechanism of action (MoA) studies for drug discovery programs. He is currently optimizing high-throughput mass spectrometry based targeted proteomic workflows to accelerate the characterization of covalent molecules from hit generation to lead optimization.
Vasudev Kantae obtained his PhD at Leiden University, Netherlands with focus in applying systems pharmacology in synergy with metabolomics, proteomics and pharmacology (PK-PD) concepts to study the lipid signalling system. Subsequently, during his postdoctoral training in collaboration with Roche Pharmaceuticals , he applied chemical proteomic strategies to study the on-target and off-target effects of drug molecules. He has published 17 manuscripts in international peer reviewed journals and is a strong advocate of adapting label-free methods in early drug discovery to accelerate and inform various projects.

Disclosure information not submitted.

Presentation(s):